Anders Essen-Möller
Chief Executive Officer Diamyd
Seminars
Wednesday 24th March 2027
Evaluating Diamyd’s Phase II/III Data & Trial to Highlight Next Steps in Antigen-Specific Therapeutic Development & Provide Direction for Ongoing Trials
8:30 am
- Reviewing the Phase II/III clinical data across the most advanced antigen-specific programs to distinguish mechanism of action from execution and trial design, providing greater confidence in assessing which approaches are most likely to deliver meaningful clinical benefit
- Unpacking the dosing, timing, and site-selection decisions in the Phase III trial to highlight endpoints and spotlight what could be changed in hindsight
- Setting out the priorities for the next year of ASIT development based on direct latestage trial experience to focus the field’s collective effort on the antigen selection, patient stratification, and delivery choices most likely to succeed
Thursday 25th March 2027
10 Years of the Antigen-Specific Immune Tolerance Summit Panel Discussion: Assessing this Year’s Presentations & Defining the Next Steps in Immune Tolerance Research for Clinical Success
3:00 pm
- Evaluating the novel mechanistic insights from this year’s program
- Assessing the preclinical data shared and looking to the next year’s clinical therapeutic landscape
- Supercharging antigen-specific immune tolerance therapies to the clinic – what can the field do together to make the promise of the technology a reality?
